Hepatitis B Vaccination in Infants
NCT01896596
Actinomycetales Infections, Bacterial Infections
London, United Kingdom
View Trial DetailsNCT Number: NCT01583049
Primary objective: This is a descriptive study and the primary objective is to determine the incidence of injection site and systemic adverse events after Triaxis administration as a 5th dose of tetanus, diphtheria and acellular pertussis vaccine in 4-6 year old children
Looking for future studies?
Notify Me4 year–6 year
All sexes
Observational
Centre 11, Almería, Spain
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 30 days following vaccination
Sanofi Pasteur, a Sanofi Company
Industry
Observational Post Authorisation Safety Study to Describe the Safety Profile of the Diphtheria, Tetanus, Acellular Pertussis Combination Vaccine, Reduced Antigen Content (Triaxis) as a 5th Dose in 4-6 Year Old Spanish Children
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01896596
Actinomycetales Infections, Bacterial Infections
London, United Kingdom
View Trial DetailsNCT07444502
Actinomycetales Infections, Bacterial Infections
Bangkok, Thailand
View Trial DetailsNCT02118961
Actinomycetales Infections, Bacterial Infections
Fukuoka, Japan
View Trial DetailsNCT03891758
Actinomycetales Infections, Bacterial Infections
Fukuoka, Japan
View Trial Details